Literature DB >> 30773798

Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.

Brian A Bergmark1, Jacob A Udell2, David A Morrow1, Petr Jarolim3, Julia F Kuder1, Scott D Solomon4, Marc A Pfeffer4, Eugene Braunwald1, Marc S Sabatine1.   

Abstract

AIMS: Klotho, an essential co-receptor for fibroblast growth factor (FGF)-23, has potentially beneficial inhibitory effects on the renin-angiotensin system. Limited data exist on the prognostic value of Klotho and FGF-23 levels in combination or their ability to predict benefit from angiotensin-converting enzyme (ACE) inhibition. METHODS AND
RESULTS: A total of 3555 patients with stable ischaemic heart disease and left ventricular ejection fraction > 40% enrolled in the PEACE trial of trandolapril vs. placebo had Klotho levels drawn at randomization. Patients were characterized by quartiles of Klotho and FGF-23 concentrations. Six-year Kaplan-Meier rates and adjusted risk were calculated in the placebo arm for the composite of cardiovascular (CV) death or hospitalization for heart failure and its components. Low [quartile (Q) 1-3] Klotho concentration was associated with an increased rate of CV death or hospitalization for heart failure as compared with Q4 (8.2% vs. 4.2%; P = 0.03). After multivariable adjustment for clinical variables and renal and CV biomarkers (estimated glomerular filtration rate, cystatin-C, urine albumin-to-creatinine ratio, FGF-23, high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein), low Klotho concentration remained strongly associated with increased risk of CV death or hospitalization for heart failure [adjusted hazard ratio (HR) 2.62; 95% confidence interval (CI) 1.35-5.08; P < 0.01]. The combination of low Klotho and high (Q4) FGF-23 concentration identified patients at particularly elevated risk (adjusted HR 3.99; 95% CI 1.67-9.56; P < 0.01). This high-risk combination additionally predicted benefit from trandolapril (HR 0.39; 95% CI 0.23-0.68; Pinteraction  < 0.01).
CONCLUSIONS: Low Klotho concentration is associated with an increased risk of CV death or heart failure hospitalization in patients with stable ischaemic heart disease. The combination of low Klotho and high FGF-23 further identifies patients at distinctly elevated risk who derive clinical benefit from the ACE-inhibitor trandolapril.
© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.

Entities:  

Keywords:  Biomarker; Fibroblast growth factor-23; Heart failure; Klotho

Year:  2019        PMID: 30773798      PMCID: PMC6458082          DOI: 10.1002/ejhf.1424

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  39 in total

Review 1.  Angiotensin-converting enzyme 2--a new cardiac regulator.

Authors:  Manfred Boehm; Elizabeth G Nabel
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

2.  KLOTHO allele status and the risk of early-onset occult coronary artery disease.

Authors:  Dan E Arking; Diane M Becker; Lisa R Yanek; Daniele Fallin; Daniel P Judge; Taryn F Moy; Lewis C Becker; Harry C Dietz
Journal:  Am J Hum Genet       Date:  2003-03-31       Impact factor: 11.025

3.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

Authors:  Eugene Braunwald; Michael J Domanski; Sarah E Fowler; Nancy L Geller; Bernard J Gersh; Judith Hsia; Marc A Pfeffer; Madeline M Rice; Yves D Rosenberg; Jean L Rouleau
Journal:  N Engl J Med       Date:  2004-11-07       Impact factor: 91.245

4.  In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage.

Authors:  Haruo Mitani; Nobukazu Ishizaka; Toru Aizawa; Minoru Ohno; Shin-ichi Usui; Toru Suzuki; Toshihiro Amaki; Ichiro Mori; Yasushi Nakamura; Misako Sato; Masaomi Nangaku; Yasunobu Hirata; Ryozo Nagai
Journal:  Hypertension       Date:  2002-04       Impact factor: 10.190

5.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Authors:  Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Nature       Date:  2006-10-29       Impact factor: 49.962

7.  Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.

Authors:  Heng Jung Hsu; Mai-Szu Wu
Journal:  Am J Med Sci       Date:  2009-02       Impact factor: 2.378

Review 8.  How fibroblast growth factor 23 works.

Authors:  Shiguang Liu; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2007-05-09       Impact factor: 10.121

9.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

Authors:  Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

10.  Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.

Authors:  Torbjørn Omland; Marc S Sabatine; Kathleen A Jablonski; Madeline Murguia Rice; Judith Hsia; Ragnhild Wergeland; Sverre Landaas; Jean L Rouleau; Michael J Domanski; Christian Hall; Marc A Pfeffer; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2007-06-29       Impact factor: 24.094

View more
  4 in total

1.  Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca2+ handling.

Authors:  José Alberto Navarro-García; Angélica Rueda; Tatiana Romero-García; Jennifer Aceves-Ripoll; Elena Rodríguez-Sánchez; Laura González-Lafuente; Carlos Zaragoza; María Fernández-Velasco; Makoto Kuro-O; Luis M Ruilope; Gema Ruiz-Hurtado
Journal:  Br J Pharmacol       Date:  2020-09-15       Impact factor: 8.739

2.  Renal Function Mediates the Association Between Klotho and Congestive Heart Failure Among Middle-Aged and Older Individuals.

Authors:  Xu Zhu; Xinyi Lu; Ting Yin; Qingqing Zhu; Shi Shi; Iokfai Cheang; Xin Yue; Yuan Tang; Shengen Liao; Yanli Zhou; Haifeng Zhang; Xinli Li; Wenming Yao
Journal:  Front Cardiovasc Med       Date:  2022-04-18

Review 3.  FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.

Authors:  Anna Kurpas; Karolina Supeł; Karolina Idzikowska; Marzenna Zielińska
Journal:  Dis Markers       Date:  2021-05-17       Impact factor: 3.434

Review 4.  The Multifunctional Contribution of FGF Signaling to Cardiac Development, Homeostasis, Disease and Repair.

Authors:  Farhad Khosravi; Negah Ahmadvand; Saverio Bellusci; Heinrich Sauer
Journal:  Front Cell Dev Biol       Date:  2021-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.